Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin
Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )
23 Sep 2021

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )
23 Sep 2021

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021

Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )
21 Sep 2021

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
21 Sep 2021

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )
21 Sep 2021

New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation

Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands
New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation ( Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands )
21 Sep 2021

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma

Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )
21 Sep 2021

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad
PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )
20 Sep 2021

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation

Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )
20 Sep 2021

Anti-cancer drug price regulation in India: Financial implications and annual savings to patients

Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Anti-cancer drug price regulation in India: Financial implications and annual savings to patients ( Dr Krishnamani Kalpathi  - American Oncology Institute, Hyderabad, India )
20 Sep 2021

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC

Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC ( Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China )
20 Sep 2021